September 22, 2011 — The 15th annual scientific meeting of the Heart Failure Society of America (HFSA) will feature a session titled "Cancer Chemotherapy and Cardiotoxicity" moderated by Daniel J. Lenihan, M.D., professor of medicine at Vanderbilt University. It will focus on the effect of cancer drugs on the presence of heart failure and how oncologists and cardiologists have developed close collaboration in order to benefit patients.
Scheduled presentations include discussions of long-term cancer care and its relation to cardiology; effects of chemotherapy on cardiotoxicity; and the effect of heart failure on therapies for cancer patients. The session highlights how physicians should treat patients and collaborate with other doctors in different areas.
"It's no longer a physician's myopic perspective when caring for a patient; we're all on the same team – the patient's team," said Lenihan. "As cardiologists engage more and more with oncologists, and vice-versa, we are not only benefiting our current patients but are also enhancing the future of modern medicine."
The session will describe the impact of chemotherapeutic agents on heart failure and will discuss recommended management options. Doctors will also discuss recent research and discoveries relating to heart failure and its connection to cancer chemotherapy.
For more information: www.hfsa.org
June 19, 2024 
